Tamar Grossman, PhDVP, Global Head of RNA & Targeted Therapeutics at Janssen Pharmaceutical Companies of John
Dr. Tamar R. Grossman is the Global Head of RNA and Targeted Therapeutics at Janssen Pharmaceutical Companies of Johnson and Johnson. Tamar is responsible for the delivery of RNA based development candidates and ADCs across all therapeutic areas. Previously, she was a Senior Director and Head of Rare Diseases at Arcturus Therapeutics where she developed RNA therapeutics across different RNA modalities including siRNA, ASO, mRNA and saRNA. Prior to Arcturus, Tamar was the Director of Translational Medicine at Ionis Pharmaceuticals where she led various antisense oligonucleotide research programs to clinical development. She received her PhD in Biochemistry from Tel-Aviv University and complete postdoctoral research training at the UCSD.